A

n effort by Sanofi to transform its dengue vaccine into a blockbuster product has, instead, turned into a scandal for the drug maker and a public health crisis in the Philippines, where the government is investigating why the vaccine was so widely adopted, despite studies suggesting its use would not be appropriate for everyone.

The issue erupted last week when the company disclosed that a new analysis found its Dengvaxia vaccine could actually make future cases of the mosquito-borne virus more severe in people who were not previously infected. And so, Sanofi changed the product labeling to limit use to people who were not exposed to Dengue in the past.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Biotech newsletter — The Readout

Your daily guide to what’s new in biotech.